<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01631669</url>
  </required_header>
  <id_info>
    <org_study_id>352511</org_study_id>
    <secondary_id>110587</secondary_id>
    <nct_id>NCT01631669</nct_id>
  </id_info>
  <brief_title>Celecoxib for Primary Prophylaxis of Combat-Related Heterotopic Ossification</brief_title>
  <official_title>Prophylaxis of Heterotopic Ossification (HO) in Wartime Extremity Injuries, a Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Walter Reed National Military Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Walter Reed National Military Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypotheses:

      H1: Celecoxib, when given less than five days after injury will result in a statistical
      decrease in the incidence and/or severity of radiographically apparent Heterotopic
      Ossification when compared to controls.

      H2a: A biomarker profile will accurately predict which patients in the treatment group will
      respond to Celecoxib prophylaxis for Heterotopic Ossification.

      H2b: A biomarker profile will accurately predict which patients in the control group are at
      highest risk of developing Heterotopic Ossification
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective, randomized, controlled clinical trial.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prophylaxis of Heterotopic Ossification (HO) in Wartime Extremity Injuries, a Randomized Clinical Trial</measure>
    <time_frame>3 years</time_frame>
    <description>Incidence and severity of HO</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prophylaxis of Heterotopic Ossification (HO) in Wartime Extremity Injuries, a Randomized Clinical Trial</measure>
    <time_frame>3 years</time_frame>
    <description>Overall rate of impaired wound healing.
Overall time to fracture union (if applicable)
Overall rate of nonunions (if applicable)
Overall rate of drug-related complications</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Ossification, Heterotopic</condition>
  <arm_group>
    <arm_group_label>Celebrex</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Receive Celebrex</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>no placebo administered</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celecoxib</intervention_name>
    <description>200 mg Q 12 hours orally</description>
    <arm_group_label>Celebrex</arm_group_label>
    <other_name>Celebrex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. ISS ≥9 (a traumatic trans-tibial amputation is an ISS of 9)

          2. Extremity Wound ≥75cm2 requiring operative intervention

          3. Minimal age of 18 years

        Exclusion Criteria:

        The following co-morbidities will result in exclusion from study:

          1. Coronary Artery Disease,

          2. Diabetes Mellitus (IDDM or T2DM),

          3. Peripheral Vascular Disease,

          4. Age &gt;65,

          5. Connective tissue disorders,

          6. Immunosuppression,

          7. Clinically-evident peptic ulcer disease,

          8. Substantial renal dysfunction (as assessed by a serum creatinine &gt;1.5 or calculated
             creatinine clearance of &lt;50),

          9. Spine-injured patients who have recently received or are going to receive spinal
             fusion as determined by the evaluating neurosurgeon or orthopaedic spine surgeon at
             LRMC,

         10. Severe penetrating or hemorrhagic traumatic brain injury,

         11. Endoscopic gastrointestinal interventions,

         12. Pregnancy or women of childbearing who does not take a pregnancy test and effective
             method of birth control.

         13. Known hypersensitivity to Celebrex, Aspirin, other NSAIDs, or Sulfonamides.

         14. History od Asthma, Urticaria, or allergic-type reactions after taking Aspirin or other
             NSAIDs.

         15. Hepatic Impairment

         16. Warfarin

         17. Lithium

         18. Drugs known to inhibit CYP2C9 Liver Enzymes

         19. Subjects known or suspected to be poor CYP2C9 metabolizers

         20. Concomitant use with ACE Inhibitors and Angiotension II Antagonists
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan A Forsberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Walter Reed National Military Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jonathan A Forsberg, MD</last_name>
    <phone>301-319-3403</phone>
    <email>jonathan.forsberg@med.navy.mil</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Frederick A Gage</last_name>
    <phone>301-319-8592</phone>
    <email>frederick.gage@med.navy.mil</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Walter Reen National Military Medical Center Bethesda</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20889</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan A Forsberg, MD</last_name>
      <phone>301-319-3403</phone>
      <email>jonathan.forsberg@med.navy.mil</email>
    </contact>
    <contact_backup>
      <last_name>Frederick A Gage</last_name>
      <phone>301-319-8592</phone>
      <email>frederick.gage@med.navy.mil</email>
    </contact_backup>
    <investigator>
      <last_name>Jonathan A Forsberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Benjamin K Potter, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eric A Elster, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frederick A Gage</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Felipe Lisboa, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tala Ghadimi, BS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Landstuhl Military Medical Center</name>
      <address>
        <city>Landstuhl</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brett Freedman, MD</last_name>
      <email>brett.freedman@amedd.army.mil</email>
    </contact>
    <investigator>
      <last_name>Brett Freedman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hunter Martin, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Forsberg JA, Pepek JM, Wagner S, Wilson K, Flint J, Andersen RC, Tadaki D, Gage FA, Stojadinovic A, Elster EA. Heterotopic ossification in high-energy wartime extremity injuries: prevalence and risk factors. J Bone Joint Surg Am. 2009 May;91(5):1084-91. doi: 10.2106/JBJS.H.00792.</citation>
    <PMID>19411456</PMID>
  </reference>
  <reference>
    <citation>Potter BK, Burns TC, Lacap AP, Granville RR, Gajewski DA. Heterotopic ossification following traumatic and combat-related amputations. Prevalence, risk factors, and preliminary results of excision. J Bone Joint Surg Am. 2007 Mar;89(3):476-86.</citation>
    <PMID>17332095</PMID>
  </reference>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 27, 2012</study_first_submitted>
  <study_first_submitted_qc>June 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 29, 2012</study_first_posted>
  <last_update_submitted>June 29, 2012</last_update_submitted>
  <last_update_submitted_qc>June 29, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 3, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ossification</keyword>
  <keyword>Heterotopic Ossification</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ossification, Heterotopic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

